Drug intelligence / Profile preview

taipan antivenom

Development stage: Preclinical
Lead developer: Instituto Clodomiro Picado
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Taipan antivenom is a polyclonal antibody preparation (hyperimmune serum) being developed by the Instituto Clodomiro Picado for the treatment of snakebite envenomation caused by the taipan (*Oxyuranus scutellatus*). The antivenom is produced by immunizing animals (typically horses) with the venom of the taipan snake, resulting in the production of specific antibodies that neutralize the various toxins present in the venom, such as neurotoxins and procoagulants. This product is currently in the preclinical development phase and is intended for human use.

Other names: Oxyuranus scutellatus antivenomtaipan snake antivenom

Targets

Prothrombin activator Oscutarin CTaipoxinPhospholipase A2 and enzymatic toxins (Oxyuranus scutellatus)

Beyond the preview

Go deeper on taipan antivenom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on taipan antivenom.

Explore the full profile